Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

Vertex stock surged 5.7% to 499.88. Shares are forming a flat base with a buy point at 510.63, according to MarketSurge. But the stock is flirting with a downtrend line between 499.09 and 500.25 ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

One of the top biotechs to watch is VertexPharmaceuticals, whose stock has formed a deep consolidation and trades just 2% from its buy point ... Investor's Business Daily. Vertex also shows ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. In plain english, this ratio subtracts FCF from net profit, and divides ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,256.99 today based on a ...

Vertex Pharmaceuticals on Monday reported disappointing ... Such standards have become a flash point in the nation’s culture wars and a source of conservative resistance to former president ...

This 11-point scale ranges from 0 (no pain ... Secondary and other endpoints were consistent with the study’s primary endpoint. Vertex also conducted post-hoc analyses to further evaluate ...